{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:59:00Z","timestamp":1793890740174,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.diabet.2026.101734","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:44:11Z","timestamp":1768549451000},"page":"101734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4460-7668","authenticated-orcid":false,"given":"Arnaud","family":"Dosda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Sabbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Henri","family":"Ducluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2026.101734_bib0001","first-page":"229\u201163","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.diabet.2026.101734_bib0002","first-page":"669\u201185","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2026.101734_bib0003","doi-asserted-by":"crossref","first-page":"85\u201199","DOI":"10.1038\/nrclinonc.2016.120","article-title":"Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?","volume":"14","author":"Klil-Drori","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0004","doi-asserted-by":"crossref","first-page":"669\u201180","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: looking forward","volume":"21","author":"Mart\u00ednez-Reyes","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.diabet.2026.101734_bib0005","doi-asserted-by":"crossref","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.diabet.2026.101734_bib0006","doi-asserted-by":"crossref","first-page":"C375\u201191","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.diabet.2026.101734_bib0007","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.3390\/ijms21165722","article-title":"Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis","volume":"21","author":"Kojima","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2026.101734_bib0008","first-page":"1340\u20118","article-title":"Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice","volume":"35","author":"Zhang","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.diabet.2026.101734_bib0009","doi-asserted-by":"crossref","first-page":"3891\u2011905","DOI":"10.2337\/db13-1169","article-title":"Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth","volume":"63","author":"Nomiyama","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2026.101734_bib0010","doi-asserted-by":"crossref","first-page":"256\u20118","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0011","article-title":"Obesity and early-onset colorectal cancer risk: emerging clinical evidence and biological mechanisms","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0012","article-title":"Microbial and metabolic profiles unveil mutualistic microbe-microbe interaction in obesity-related colorectal cancer","volume":"5","author":"Li","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.diabet.2026.101734_bib0013","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.3390\/ijms24076192","article-title":"Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk","volume":"24","author":"Wilson","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2026.101734_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2026.101734_bib0015","doi-asserted-by":"crossref","first-page":"2930\u201141","DOI":"10.1200\/JCO-25-00148","article-title":"Diabetes and colorectal cancer risk and survival according to tumor immunity status","volume":"43","author":"Wankhede","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0016","doi-asserted-by":"crossref","first-page":"1186\u201193","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0017","article-title":"Efficacy of three modern anti-diabetic drugs on survival outcomes of lung cancer patients with type 2 diabetes in China","volume":"15","author":"Chen","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0018","first-page":"18","article-title":"The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration","volume":"44","author":"Cencioni","year":"2025","journal-title":"J Exp Clin Cancer Res CR"},{"key":"10.1016\/j.diabet.2026.101734_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.20517\/cdr.2024.116","article-title":"The emerging role of GLP-1 receptor agonists in treating or preventing cancer","volume":"7","author":"Benjamin","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.diabet.2026.101734_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101695","article-title":"Reduced risks of colorectal cancer with GLP-1RAs in type 2 diabetes: a nationwide cohort study using a target trial emulation framework","volume":"51","author":"Wu","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2026.101734_bib0021","doi-asserted-by":"crossref","first-page":"3109\u201116","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0022","doi-asserted-by":"crossref","first-page":"277\u201184","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64774-2","article-title":"Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo","volume":"14","author":"Trakoonsenathong","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2026.101734_bib0024","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194743","article-title":"GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research","volume":"135","author":"Valencia-Rinc\u00f3n","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2026.101734_bib0025","doi-asserted-by":"crossref","first-page":"689\u2011703","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2026.101734_bib0026","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12885-023-11077-w","article-title":"High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.diabet.2026.101734_bib0027","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.diabet.2026.101734_bib0028","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00432-025-06154-5","article-title":"Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway","volume":"151","author":"Wang","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.diabet.2026.101734_bib0029","doi-asserted-by":"crossref","first-page":"103\u201113","DOI":"10.1530\/JME-19-0186","article-title":"Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells","volume":"64","author":"Zhao","year":"2020","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.diabet.2026.101734_bib0030","doi-asserted-by":"crossref","first-page":"2777\u201189","DOI":"10.1210\/clinem\/dgaf053","article-title":"Semaglutide reprograms macrophages via the GLP-1R\/PPARG\/ACSL1 pathway to suppress papillary thyroid carcinoma growth","volume":"110","author":"Wang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2026.101734_bib0031","doi-asserted-by":"crossref","first-page":"463\u201174","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabet.2026.101734_bib0032","doi-asserted-by":"crossref","first-page":"797\u2011808","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabet.2026.101734_bib0033","doi-asserted-by":"crossref","first-page":"653\u201162","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2026.101734_bib0034","doi-asserted-by":"crossref","first-page":"2221\u201132","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101734_bib0035","doi-asserted-by":"crossref","first-page":"109\u201121","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:19:47Z","timestamp":1777288787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363626000133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1262363626000133"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101734","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101734"}}